PHIO Stock Catalyst: Phio Pharmaceuticals Reports 100% Tumor Clearance in Two Patients Using PH-762

Jan 13, 2025 · 7:46am ET

Results from Phase 1b cancer study.

Max move

+519.6%

High of day $9.79

Sparker timei

7:46am ET

PHIO · Jan 13, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that its Phase 1b cancer study using PH-762 demonstrated 100% tumor clearance in two patients.

The study involved the use of PH-762, a proprietary immunotherapeutic, in cancer treatment. The company reported that two patients achieved complete tumor clearance.

As of the latest data, Phio Pharmaceuticals has a free float of 5,677,000 shares and 11,039,900 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PHIO sparks.

Download Sniper App →

Catch the next PHIO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →